Related Experiment Video
Updated: Jun 5, 2026
09:12
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
Published on: February 3, 2023
AKR1B10 Serves as a Specific Biomarker for the Identification of Hepatocellular Ballooning Degeneration in MASH
Jin-Zhong Li1, Li-Li Zhang2, Li-Hong Ye3
1Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Summary
AKR1B10 is a promising biomarker for detecting hepatocyte ballooning in metabolic dysfunction-associated steatohepatitis (MASH). Elevated serum AKR1B10 levels accurately identify MASH patients and correlate with disease severity.
Area of Science:
- Hepatology
- Biomarker Discovery
- Molecular Pathology
Background:
- Hepatocellular ballooning degeneration is a key feature distinguishing metabolic dysfunction-associated steatohepatitis (MASH) from metabolic dysfunction-associated steatotic liver (MASL).
- Currently, there is a lack of specific biomarkers to identify and quantify hepatocyte ballooning in MASH.
- Understanding the molecular mechanisms and identifying reliable biomarkers for ballooning is crucial for MASH diagnosis and management.
Purpose of the Study:
- To investigate the role of AKR1B10 as a potential biomarker for hepatocyte ballooning in MASH.
- To analyze the spatial expression of AKR1B10 in liver tissue and its correlation with ballooning severity.
- To evaluate the diagnostic performance of serum AKR1B10 levels for identifying MASH patients with ballooning.
Main Methods:
- Utilized spatial and single-cell transcriptomic analyses to examine hepatocyte ballooning.
- Performed H&E staining and immunofluorescence to analyze AKR1B10 and CK8/18 expression in human liver samples.
- Quantified serum AKR1B10 levels in 284 patients with various liver conditions and performed logistic regression analysis.
Main Results:
- Spatial transcriptomics revealed significant AKR1B10 enrichment in ballooned hepatocytes.
- Immunostaining confirmed AKR1B10 localization in ballooning regions, correlating with CK8/18 loss.
- Serum AKR1B10 levels were significantly higher in MASH patients and correlated with ballooning severity (R=0.624), demonstrating a diagnostic AUC of 0.863.
Conclusions:
- AKR1B10 is a potential diagnostic biomarker for hepatocyte ballooning in MASH, exhibiting spatial specificity.
- Serum AKR1B10 levels offer clinical value for noninvasive diagnosis and disease stratification of MASH patients.
- AKR1B10 may also serve as a therapeutic biomarker for monitoring treatment response in MASH.
